Pet Cancer Therapeutics Market (Updated Version Available)

Pet cancer therapeutics are the novel drug molecules that exhibit high potential to reduce the effects of cancer, giving access to comprehensive cancer care with minimum side effects. Cancer therapies aims to permanently eradicate the cancerous cells prevalent in pets. The veterinarian recommends specific treatment program such as targeted therapy and combination therapy or chemotherapy depending on the type of cancer, stage, and nature of the cancer.
The ongoing research activities undertaken by the scientists for the development of novel formulations and therapies is expected to accelerate the market growth.
In 2019, the market size of Pet Cancer Therapeutics is 180 million US$ and it will reach 330 million US$ in 2025, growing at a CAGR of 7.7% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Pet Cancer Therapeutics.

This report studies the global market size of Pet Cancer Therapeutics, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Pet Cancer Therapeutics sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Aratana Therapeutics, Inc
AB Science
Boehringer Ingelheim International GmbH
Zenoaq
Morphogenesis, Inc
VetDC, Inc
Karyopharm Therapeutics, Inc
Rhizen Pharmaceutical SA
Regeneus Ltd.
Oasmia Pharmaceuticals AB
Zoetis

Market Segment by Product Type
Chemotherapy
Targeted Therapy
Combination Therapy
Immunotherapy

Market Segment by Application
Lymphoma
Mast Cell Cancer
Melanoma
Mammary
Squamous Cell Cancer
Others

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)